CoChat
Sign Up
Cited by 308Monoclonal and Polyclonal Antibodies Researchvaccines and immunoinformatics approachesComputational Drug Discovery Methods

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning

Open access
Mason, Derek M., Friedensohn, Simon, Weber, Cédric R., Jordi, Christian, Wagner, Bastian, Meng, Simon M., Ehling, Roy A., Bonati, Lucia, Dahinden, Jan, Gainza, Pablo, Correia, Bruno E., Reddy, Sai T.·2021·Nature Biomedical Engineering
DOI 10.1038/s41551-021-00699-9
Open this paper in CoChat — free account

Abstract

The optimization of therapeutic antibodies is time-intensive and resource-demanding, largely because of the low-throughput screening of full-length antibodies (approximately 1 × 10 3 variants) expressed in mammalian cells, which typically results in few optimized leads. Here we show that optimized antibody variants can be identified by predicting antigen specificity via deep learning from a massively diverse space of antibody sequences. To produce data for training deep neural networks, we deep-sequenced libraries of the therapeutic antibody trastuzumab (about 1 × 10 4 variants), expressed in a mammalian cell line through site-directed mutagenesis via CRISPR-Cas9-mediated homology-directed repair, and screened the libraries for specificity to human epidermal growth factor receptor 2 (HER2). We then used the trained neural networks to screen a computational library of approximately 1 × 10 8 trastuzumab variants and predict the HER2-specific subset (approximately 1 × 10 6 variants), which can then be filtered for viscosity, clearance, solubility and immunogenicity to generate thousands of highly optimized lead candidates. Recombinant expression and experimental testing of 30 randomly selected variants from the unfiltered library showed that all 30 retained specificity for HER2. Deep learning may facilitate antibody engineering and optimization.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41551-021-00699-9

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 59 references

Research works printed but not linked: 1

  1. Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. Preprint at https://arxiv.org/abs/1703.01365 (2017). · arXiv

Cited by

Sorted by citations

Items 201–300 of 308

Related

See all

Metadata

Authors
Mason, D. M., Friedensohn, S., Weber, C. R., Jordi, C., Wagner, B., Meng, S. M., Ehling, R. A., Bonati, L., Dahinden, J., Gainza, P., Correia, B. E., & Reddy, S. T.
Affiliations
  • ETH Zurich (CH)
  • École Polytechnique Fédérale de Lausanne (CH)
Corresponding author
Reddy, Sai T.
ORCID
Venue
Nature Biomedical Engineering
Publisher
Springer Science and Business Media LLC
Published
2021-04-15
Volume
5
Issue
6
Pages
600-612
ISSN
2157-846X (ISSN-L)
DOI
10.1038/s41551-021-00699-9
OpenAlex
W3156522942
Cited by
308
References
59
Citations by year
2026: 55 · 2025: 66 · 2024: 62 · 2023: 60 · 2022: 48 · 2021: 17
FWCI
24.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Biomedical Engineering (publishedVersion)
  • PubMed (publishedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Funders
NCCR Molecular Systems Engineering
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
therapeutic antibodies, antibody engineering, trastuzumab, HER2, deep learning, antibody optimization
MeSH terms
Trastuzumab, Deep Learning, Amino Acid Sequence, Animals, Antibody Affinity, Antibody Specificity, Antigens, Humans, Hybridomas, Protein Binding, Protein Engineering, Mutagenesis, Site-Directed, Erb-b2 Receptor Tyrosine Kinases, Sequence Analysis, Protein, Recombinational DNA Repair, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review